Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Liu, Liangliang ^a   Dong, Xuesen ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; ANDROGEN RECEPTOR; BUPARLISIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; WORTMANNIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; ANDROSTANE DERIVATIVE; AR PROTEIN, HUMAN; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ALTERNATIVE RNA SPLICING; ANDROGEN RECEPTOR GENE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOLECULARLY TARGETED THERAPY; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA DEGRADATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; RNA SPLICING; RNA STABILITY; TUMOR CELL LINE;

ANDROSTADIENES; CELL LINE, TUMOR; CHROMONES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; RECEPTORS, ANDROGEN; RNA SPLICING; RNA STABILITY; TRANSCRIPTION INITIATION, GENETIC;

EID: 84910138680     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108780     Document Type: Article

References (42)

1. Lorente D, De Bono JS (2014) Molecular alterations and emerging targets in castration resistant prostate cancer. Eur J Cancer 50: 753-764.
2. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, et al. (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55: 3068-3072.
3. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61: 2892-2898.
4. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406.
5. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261.
6. Culig Z, Klocker H, Bartsch G, Steiner H, Hobisch A (2003) Androgen receptors in prostate cancer. J Urol 170: 1363-1369.
7. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, et al. (2000) Androgen receptor mutations in prostate cancer. Cancer Res 60: 944-949.
8. Ford OH 3rd, Gregory CW, Kim D, Smitherman AB, Mohler JL (2003) Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 170: 1817-1821.
9. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, et al. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555.
10. Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A (2004) Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 92: 265-271.
11. Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, et al. (2007) Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 67: 3422-3430.
12. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM (2007) Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 120: 719-733.
13. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313.
14. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, et al. (2009) Ligandin-dependent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22.
15. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, et al. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-2730.
16. Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71: 1656-1667.
17. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, et al. (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107: 16759-16765.
18. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, et al. (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6: e19059.
19. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
20. Bitting RL, Armstrong AJ (2013) Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 20: R83-99.
21. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, et al. (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19: 792-804.
22. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, et al. (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19: 575-586.
23. Davies SP, Reddy H, Caivano M, Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
24. Jacobs MD, Black J, Futer O, Swenson L, Hare B, et al. (2005) Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 280: 13728-13734.
25. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
26. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
27. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, et al. (2014) Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 33: 3140-3150.
28. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, et al. (2012) Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72: 3457-3462.
29. Yu Y, Liu L, Xie N, Xue H, Fazli L, et al. (2013) Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. J Clin Endocrinol Metab 98: 2887-2896.
30. Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, et al. (2014) Prostate stromal cells express the progesterone receptor to control cancer cell mobility. PLoS One 9: e92714.
31. Liu L, Li Y, Xie N, Shynlova O, Challis JR, et al. (2013) Proliferative action of the androgen receptor in human uterine myometrial cells-a key regulator for myometrium phenotype programming. J Clin Endocrinol Metab 98: 218-227.
32. Zhang MX, Ou H, Shen YH, Wang J, Coselli J, et al. (2005) Regulation of endothelial nitric oxide synthase by small RNA. Proc Natl Acad Sci U S A 102: 16967-16972.
33. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248.
34. Arcaro A, Wymann MP (1993) Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 296 (Pt 2): 297-301.
35. Burger MT, Pecchi S, Wagman A, Ni ZJ, Knapp M, et al. (2011) Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett 2: 774-779.
36. Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, et al. (2000) 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem 43: 3045-3051.
37. Addie M, Ballard P, Buttar D, Crafter C, Currie G, et al. (2013) Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem 56: 2059-2073.
38. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, et al. (2012) Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 11: 873-887.
39. Zhao JC, Yu J, Runkle C, Wu L, Hu M, et al. (2012) Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res 22: 322-331.
40. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 101: 811-816.
41. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, et al. (1998) Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58: 204-209.
42. De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, et al. (2014) Androgen Deprivation Induces Phenotypic Plasticity and Promotes Resistance to Molecular Targeted Therapy in a PTEN-deficient Mouse Model of Prostate Cancer. Carcinogenesis.